Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Rare Tumour 1HER2-positive Breast Cancer 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Breast Cancer With Brain Metastasis 1Brain Neoplasms 1

Interventions

Carboplatin 35Pemetrexed 28Cisplatin 23Drug Therapy 22osimertinib 18aflutinib 11Paclitaxel 11tislelizumab 10pembrolizumab 10Surgical Procedures, Operative 10Docetaxel 10Radiotherapy 8Magnetic Resonance Spectroscopy 8anlotinib 7Specimen Handling 7Bevacizumab 7130-nm albumin-bound paclitaxel 7toripalimab 6cemiplimab 6Immunotherapy 6sintilimab 5ensartinib 5durvalumab 5Radiosurgery 5Platinum Compounds 5Nivolumab 5trametinib 4aumolertinib 4Observation 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Non-Small-Cell Lung × neratinib × Clear all
NCT06519110 2024-07-25

CVL009-C2001

Convalife (Shanghai) Co., Ltd.

Phase 2 Not yet recruiting
60 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡